Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.84 |
| ▸ | CCR5 | P51681 | 6/20 | 0.42 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945719 | 0.92 | CCR2 (1.00) | CCR2CCR5CCRL2CACNA1BSPR | |
| SCHEMBL15032048 | 0.89 | CCR2 (0.75) | CCR2CCR5RBP4FFAR1RECQL | |
| SCHEMBL15032052 | 0.87 | CCR2 (0.71) | CCR2CCR5FFAR1RECQLSCN9A | |
| SCHEMBL14945908 | 0.84 | CCR2 (0.79) | CCR2CCR5SCN9ALMNA | |
| SCHEMBL12184755 | 0.84 | CCR2 (0.85) | CCR2CCR5CCRL2CACNA1BGPR119 | |
| SCHEMBL12184105 | 0.84 | CCR2 (0.78) | CCR2CCR5SCN9ALMNA | |
| SCHEMBL14945907 | 0.83 | CCR2 (0.79) | CCR2CCR5SPRFFAR1RECQL | |
| SCHEMBL12184055 | 0.83 | CCR2 (0.79) | CCR2CCR5TRPV4SCN9A | |
| SCHEMBL12184102 | 0.83 | CCR2 (0.76) | CCR2CCR5SPRRECQLSCN9A | |
| SCHEMBL12184078 | 0.82 | CCR2 (0.76) | CCR2CCR5CCRL2SCN9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721025-B1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-11-25 | — | — | EP | disclosed |
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150354-A1 | NEW SELECTIVE CCR2 ANTAGONISTS | CCR2, CCRL2, CXCR2 | CCR2 1/4885CCR5 6/4885CCRL2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.